Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01434147
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : March 7, 2014
Hoffmann-La Roche
Information provided by (Responsible Party):
Austrian Breast & Colorectal Cancer Study Group

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : August 2013
  Actual Study Completion Date : August 2013
Publications of Results:
Other Publications:
NIH Consensus Conference. JAMA 1990;264:1440-50
Budach et al. Stellenwert der Radio- und Radiochemotherapie beim Rektumkarzinom. Onkologe 1998;4:40-48
Tebutt et al. International randomized phase III study of Capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. Proc ASCO 2010, #3538
Haller et al. A randomized phase III trial of Capecitabin + oxaliplatin (XELOX) versus bolus 5-FU/LV for stage III colon cancer. ECCO/ESMO 2009, #LBA5.
NCCN Clinical Practice guidelines in Oncology (NCCN GuidelinesTM) Rectal cancer version 2.2011.
Marechal et al. Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study. Proc ASCO 2010: abstract 3637
Dipetrillo et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation in clinical stage II-III rectal cancer. J Clin Oncol 27 (suppl):170s, abstr 4105.
Aschele et al. Oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the studio terapia adiuvante retto (STAR)-01 randomized phase III trial. J Clin Oncol 27 (suppl):170s, abstr CRA4008
Francois et al., J Clin Oncol 1999;17:2396-2402
S3-Leitlinie "Kolorektales Karzinom, Arbeitsgruppe "Workflow Rektumkarzinom" Zentralbl Chir 2006; 131:285-297